{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:42:09Z","timestamp":1784864529708,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14404-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:56:50Z","timestamp":1751353010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Chaoyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"14404_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.","journal-title":"Biol Res"},{"issue":"7","key":"14404_CR2","first-page":"8500","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 2015;8(7):8500\u20135.","journal-title":"Int J Clin Exp Pathol"},{"key":"14404_CR3","first-page":"743193","volume":"2012","author":"Z Mitri","year":"2012","unstructured":"Mitri Z, Constantine T, O\u2019Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.","journal-title":"Chemother Res Pract"},{"issue":"5","key":"14404_CR4","doi-asserted-by":"publisher","first-page":"e000279","DOI":"10.1136\/esmoopen-2017-000279","volume":"2","author":"CM Connell","year":"2017","unstructured":"Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279.","journal-title":"ESMO Open"},{"issue":"3","key":"14404_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2174\/156800909788166484","volume":"9","author":"BC Browne","year":"2009","unstructured":"Browne BC, O\u2019Brien N, Duffy MJ, Crown J, O\u2019Donovan N. HER-2 signaling and Inhibition in breast cancer. Curr Cancer Drug Targets. 2009;9(3):419\u201338.","journal-title":"Curr Cancer Drug Targets"},{"key":"14404_CR6","doi-asserted-by":"crossref","unstructured":"Fernandes CL, Silva DJ, Mesquita A. Novel HER-2 targeted therapies in breast Cancer. Cancers. 2023;16(1).","DOI":"10.3390\/cancers16010087"},{"issue":"3","key":"14404_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.5306\/wjco.v5.i3.440","volume":"5","author":"G Recondo","year":"2014","unstructured":"Recondo G, D\u00ecaz Canton E, de la Vega M, Greco M, Recondo G, Valsecchi ME. Therapeutic options for HER-2 positive breast cancer: perspectives and future directions. World J Clin Oncol. 2014;5(3):440\u201354.","journal-title":"World J Clin Oncol"},{"issue":"2","key":"14404_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","volume":"30","author":"S Maximiano","year":"2016","unstructured":"Maximiano S, Magalh\u00e3es P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast Cancer. BioDrugs: Clin Immunotherapeutics Biopharmaceuticals Gene Therapy. 2016;30(2):75\u201386.","journal-title":"BioDrugs: Clin Immunotherapeutics Biopharmaceuticals Gene Therapy"},{"issue":"4","key":"14404_CR9","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/jcp.29216","volume":"235","author":"A Derakhshani","year":"2020","unstructured":"Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142\u201356.","journal-title":"J Cell Physiol"},{"issue":"11","key":"14404_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1634\/theoncologist.2009-0142","volume":"14","author":"V Roy","year":"2009","unstructured":"Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009;14(11):1061\u20139.","journal-title":"Oncologist"},{"issue":"2","key":"14404_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","volume":"40","author":"I K\u00fcmler","year":"2014","unstructured":"K\u00fcmler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259\u201370.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"14404_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast cancer. 2021;7(1):56.","journal-title":"NPJ Breast cancer"},{"issue":"9816","key":"14404_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (London England). 2012;379(9816):633\u201340.","journal-title":"Lancet (London England)"},{"issue":"12","key":"14404_CR14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","volume":"14","author":"A Robidoux","year":"2013","unstructured":"Robidoux A, Tang G, Rastogi P, Geyer CE Jr., Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183\u201392.","journal-title":"Lancet Oncol"},{"issue":"16","key":"14404_CR15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","volume":"30","author":"V Guarneri","year":"2012","unstructured":"Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncology: Official J Am Soc Clin Oncol. 2012;30(16):1989\u201395.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"2","key":"14404_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdu551","volume":"26","author":"H Bonnefoi","year":"2015","unstructured":"Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Annals Oncology: Official J Eur Soc Med Oncol. 2015;26(2):325\u201332.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"5","key":"14404_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/bjc.2013.831","volume":"110","author":"E Alba","year":"2014","unstructured":"Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, S\u00e1nchez-Rovira P, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM\/2006-14 trial. Br J Cancer. 2014;110(5):1139\u201347.","journal-title":"Br J Cancer"},{"issue":"10","key":"14404_CR18","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.2013.51.4737","volume":"32","author":"V Guarneri","year":"2014","unstructured":"Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2014;32(10):1050\u20137.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"14404_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12916-022-02708-3","volume":"20","author":"J Wu","year":"2022","unstructured":"Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498.","journal-title":"BMC Med"},{"issue":"7\u20138","key":"14404_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000531492","volume":"46","author":"Y Ding","year":"2023","unstructured":"Ding Y, Mo W, Xie X, Wang O, He X, Zhao S, et al. Neoadjuvant Pyrotinib plus trastuzumab, docetaxel, and carboplatin in early or locally advanced human epidermal receptor 2-Positive breast Cancer in china: A multicenter, randomized, Double-Blind, Placebo-Controlled phase 2 trial. Oncol Res Treat. 2023;46(7\u20138):303\u201311.","journal-title":"Oncol Res Treat"},{"issue":"14","key":"14404_CR21","doi-asserted-by":"publisher","first-page":"15090","DOI":"10.1002\/cam4.6180","volume":"12","author":"Y Yu","year":"2023","unstructured":"Yu Y, Huang K, Lin Y, Zhang J, Song C. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis. Cancer Med. 2023;12(14):15090\u2013100.","journal-title":"Cancer Med"},{"issue":"6","key":"14404_CR22","doi-asserted-by":"publisher","first-page":"188969","DOI":"10.1016\/j.bbcan.2023.188969","volume":"1878","author":"L Li","year":"2023","unstructured":"Li L, Zhang D, Wu Y, Wang J, Ma F. Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: A systematic review and meta-analysis. Biochim Et Biophys Acta Reviews cancer. 2023;1878(6):188969.","journal-title":"Biochim Et Biophys Acta Reviews cancer"},{"key":"14404_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2021.05.018","volume":"153","author":"V Guarneri","year":"2021","unstructured":"Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial. Eur J Cancer. 2021;153:133\u201341.","journal-title":"Eur J Cancer"},{"issue":"3","key":"14404_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351\u201360.","journal-title":"Lancet Oncol"},{"issue":"29","key":"14404_CR25","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-Positive metastatic breast Cancer with prior taxanes, anthracyclines, and\/or trastuzumab: A randomized, phase II study. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(29):2610\u20139.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14404_CR26","first-page":"67","volume":"40","author":"T Takano","year":"2018","unstructured":"Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, et al. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B\/ELTOP. Breast (Edinburgh. Scotland). 2018;40:67\u201375.","journal-title":"Scotland)"},{"issue":"12","key":"14404_CR27","doi-asserted-by":"publisher","first-page":"e1909","DOI":"10.1002\/onco.13546","volume":"25","author":"J Xuhong","year":"2020","unstructured":"Xuhong J, Qi X, Tang P, Fan L, Chen L, Zhang F, et al. Neoadjuvant Pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-Positive breast cancer: A phase II clinical trial. Oncologist. 2020;25(12):e1909\u201320.","journal-title":"Oncologist"},{"issue":"7","key":"14404_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14737140.2024.2350105","volume":"24","author":"R Chen","year":"2024","unstructured":"Chen R, Yu Y, Zhang J, Song C, Wang C. Efficacy and safety of neoadjuvant therapy for HR-positive\/HER2-negative early breast cancer: a bayesian network meta-analysis. Expert Rev Anticancer Ther. 2024;24(7):599\u2013611.","journal-title":"Expert Rev Anticancer Ther"},{"key":"14404_CR29","doi-asserted-by":"crossref","unstructured":"Fernandes CL, Silva DJ, Mesquita A. Novel HER-2 targeted therapies in breast Cancer. Cancers (Basel) 2023; 16.","DOI":"10.3390\/cancers16010087"},{"issue":"2","key":"14404_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","volume":"46","author":"O Cooper","year":"2014","unstructured":"Cooper O, Mamelak A, Bannykh S, Carmichael J, Bonert V, Lim S, Cook-Wiens G, Ben-Shlomo A. Prolactinoma erbb receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014;46(2):318\u201327.","journal-title":"Endocrine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14404-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:56:53Z","timestamp":1751353013000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14404"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14404-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies included in this systematic review and network meta-analysis were approved by their respective Institutional Review Boards (IRBs) or Ethics Committees. The approval details for each study can be found in the original publications referenced in this manuscript. All participants included in the studies reviewed provided written informed consent prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1072"}}